Abstract
There is a train of thought that lipid therapies may delay or limit the impact of neuronal loss and poor patient outcomes of neurodegenerative diseases (NDDs). A variety of medicines including lipid lowering modifiers (LLMs) are prescribed in NDDs. This paper summarizes the findings of clinical and observational trials including systematic reviews and meta-analyses relating to LLM use in NDDs published in the last 15 years thus providing an up-to-date evidence pool. Three databases were searched PubMed, CINAHL, and Web of Science using key terms relating to the review question. The findings confirm the benefit of LLMs in hyperlipidemic patients with or without cardiovascular risk factors due to their pleotropic effects. In NDDs LLMs are proposed to delay disease onset and slow the rate of progression. Clinical observations show that LLMs protect neurons from α-synuclein, tau, and Aβ toxicity, activation of inflammatory processes, and ultimately oxidative injury. Moreover, current meta-analyses and clinical trials indicated low rates of adverse events with LLMs when used as monotherapy. LLMs appear to have favorable safety and tolerability profiles with few patients stopping treatment due to severe adverse effects. Our collated evidence thus concludes that LLMs have a role in NDDs but further work is needed to understand the exact mechanism of action and reach more robust conclusions on where and when it is appropriate to use LLMs in NDDs in the clinic.
-
Author contribution: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
-
Research funding: None.
-
Conflict of interest statement: None.
References
Abdul-Rahman, T., Bukhari, S.M.A., Herrera, E.C., Awuah, W.A., Lawrence, J., de Andrade, H., Patel, N., Shah, R., Shaikh, R., Capriles, C.A.A., et al.. (2022). Lipid lowering therapy: an era beyond statins. Curr. Probl. Cardiol. 47: 101342, https://doi.org/10.1016/j.cpcardiol.2022.101342.Search in Google Scholar PubMed
Adhikari, A., Tripathy, S., Chuzi, S., Peterson, J., and Stone, N.J. (2021). Association between statin use and cognitive function: a systematic review of randomized clinical trials and observational studies. J. Clin. Lipidol. 15: 22–32.e12, https://doi.org/10.1016/j.jacl.2020.10.007.Search in Google Scholar PubMed
Alsehli, A.M., Olivo, G., Clemensson, L.E., Williams, M.J., and Schiöth, H.B. (2020). The cognitive effects of statins are modified by age. Sci. Rep. 10: 1–14, https://doi.org/10.1038/s41598-020-63035-2.Search in Google Scholar PubMed PubMed Central
Alsheikh-Ali, A.A. and Karas, R.H. (2007). Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system). Am. J. Cardiol. 99: 379–381, https://doi.org/10.1016/j.amjcard.2006.08.044.Search in Google Scholar PubMed
Alsheikh-Ali, A.A. and Karas, R.H. (2008). The safety of niacin in the US Food and Drug Administration adverse event reporting database. Am. J. Cardiol. 101: S9–S13, https://doi.org/10.1016/j.amjcard.2008.02.027.Search in Google Scholar PubMed
Amend, K.L., Landon, J., Thyagarajan, V., Niemcryk, S., and McAfee, A. (2011). Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population. Ann. Pharmacother. 45: 1230–1239, https://doi.org/10.1345/aph.1q110.Search in Google Scholar
Ancelin, M.-L., Carrière, I., Barberger-Gateau, P., Auriacombe, S., Rouaud, O., Fourlanos, S., Berr, C., Dupuy, A.-M., and Ritchie, K. (2012). Lipid lowering agents, cognitive decline, and dementia: the three-city study. J. Alzheim. Dis. 30: 629–637, https://doi.org/10.3233/jad-2012-120064.Search in Google Scholar
Armitage, J. (2007). The safety of statins in clinical practice. Lancet 370: 1781–1790, https://doi.org/10.1016/s0140-6736(07)60716-8.Search in Google Scholar PubMed
Arvanitakis, Z., Schneider, J., Wilson, R., Bienias, J., Kelly, J., Evans, D., and Bennett, D. (2008). Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 70: 1795–1802, https://doi.org/10.1212/01.wnl.0000288181.00826.63.Search in Google Scholar PubMed
Avitabile, N., Banka, A., and Fonseca, V.A. (2011). Safety evaluation of colesevelam therapy to achieve glycemic and lipid goals in type 2 diabetes. Expet Opin. Drug Saf. 10: 305–310, https://doi.org/10.1517/14740338.2011.548320.Search in Google Scholar PubMed
Bahrami, A., Bo, S., Jamialahmadi, T., and Sahebkar, A. (2020). Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ageing: molecular mechanisms. Ageing Res. Rev. 58: 101024, https://doi.org/10.1016/j.arr.2020.101024.Search in Google Scholar PubMed
Bahrami, A., Parsamanesh, N., Atkin, S.L., Banach, M., and Sahebkar, A. (2018). Effect of statins on toll-like receptors: a new insight to pleiotropic effects. Pharmacol. Res. 135: 230–238, https://doi.org/10.1016/j.phrs.2018.08.014.Search in Google Scholar PubMed
Baigent, C., Landray, M.J., Reith, C., Emberson, J., Wheeler, D.C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al.. (2011). The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet 377: 2181–2192, https://doi.org/10.1016/s0140-6736(11)60739-3.Search in Google Scholar PubMed PubMed Central
Bajaj, N.S., Patel, N., Kalra, R., Ahmad, A., Venkatraman, A., Arora, G., and Arora, P. (2018). Neurological effects of proprotein convertase subtilisin/kexin type 9 inhibitors: direct comparisons. Eur. Heart J. Qual. Care Clin. Outcomes 4: 132–141, https://doi.org/10.1093/ehjqcco/qcx037.Search in Google Scholar PubMed PubMed Central
Ballantyne, C.M., Davidson, M.H., MacDougall, D.E., Bays, H.E., DiCarlo, L.A., Rosenberg, N.L., Margulies, J., and Newton, R.S. (2013). Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J. Am. Coll. Cardiol. 62: 1154–1162, https://doi.org/10.1016/j.jacc.2013.05.050.Search in Google Scholar PubMed
Ballantyne, C.M., Davidson, M.H., McKenney, J., Keller, L.H., Bajorunas, D.R., and Karas, R.H. (2008). Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs. simvastatin monotherapy in patients with increased non–HDL cholesterol (from the SEACOAST I Study). Am. J. Cardiol. 101: 1428–1436, https://doi.org/10.1016/j.amjcard.2008.02.092.Search in Google Scholar PubMed
Banach, M., Serban, C., Ursoniu, S., Rysz, J., Muntner, P., Toth, P.P., Jones, S.R., Rizzo, M., Glasser, S.P., Watts, G.F., et al.. (2015). Statin therapy and plasma coenzyme Q10 concentrations - a systematic review and meta-analysis of placebo-controlled trials. Pharmacol. Res. 99: 329–336, https://doi.org/10.1016/j.phrs.2015.07.008.Search in Google Scholar PubMed
Banerjee, Y., Santos, R.D., Al-Rasadi, K., and Rizzo, M. (2016). Targeting PCSK9 for therapeutic gains: have we addressed all the concerns? Atherosclerosis 248: 62–75, https://doi.org/10.1016/j.atherosclerosis.2016.02.018.Search in Google Scholar PubMed
Barkas, F., Elisaf, M., and Milionis, H. (2015). Statins decrease the risk of stroke in individuals with heterozygous familial hypercholesterolemia: a systematic review and meta-analysis. Atherosclerosis 243: 60–64, https://doi.org/10.1016/j.atherosclerosis.2015.08.038.Search in Google Scholar PubMed
Barone, E., Di Domenico, F., and Butterfield, D.A. (2014). Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets. Biochem. Pharmacol. 88: 605–616, https://doi.org/10.1016/j.bcp.2013.10.030.Search in Google Scholar PubMed PubMed Central
Bays, H.E., Banach, M., Catapano, A.L., Duell, P.B., Gotto, A.M.Jr, Laufs, U., Leiter, L.A., Mancini, G.J., Ray, K.K., Bloedon, L.T., et al.. (2020). Bempedoic acid safety analysis: pooled data from four phase 3 clinical trials. J. Clin. Lipidol. 14: 649–659, https://doi.org/10.1016/j.jacl.2020.08.009.Search in Google Scholar PubMed
Bays, H.E., Neff, D., Tomassini, J.E., and Tershakovec, A.M. (2008). Ezetimibe: cholesterol lowering and beyond. Expert Rev. Cardiovasc Ther. 6: 447–470, https://doi.org/10.1586/14779072.6.4.447.Search in Google Scholar PubMed
Bhagavathula, A.S., Al Matrooshi, N.O., Clark, C.C., and Rahmani, J. (2020). Bempedoic acid and ezetimibe for the treatment of hypercholesterolemia: a systematic review and meta-analysis of randomized Phase II/III trials. Clin. Drug Invest.: 1–10, https://doi.org/10.1007/s40261-020-00989-1.Search in Google Scholar PubMed
Birnbaum, G., Cree, B., Altafullah, I., Zinser, M., and Reder, A. (2008). Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 71: 1390–1395, https://doi.org/10.1212/01.wnl.0000319698.40024.1c.Search in Google Scholar PubMed
Blanco, M., Nombela, F., Castellanos, M.a., Rodriguez-Yanez, M., Garcia-Gil, M., Leira, R., Lizasoain, I., Serena, J., Vivancos, J., Moro, M., et al.. (2007). Statin treatment withdrawal in ischemic stroke: a controlled randomized study. Neurology 69: 904–910, https://doi.org/10.1212/01.wnl.0000269789.09277.47.Search in Google Scholar PubMed
Bland, A.R., Payne, F.M., Ashton, J.C., Jamialahmadi, T., and Sahebkar, A. (2022). The cardioprotective actions of statins in targeting mitochondrial dysfunction associated with myocardial ischaemia-reperfusion injury. Pharmacol. Res. 175: 105986, https://doi.org/10.1016/j.phrs.2021.105986.Search in Google Scholar PubMed
Blasko, I., Jungwirth, S., Jellinger, K., Kemmler, G., Krampla, W., Weissgram, S., Wichart, I., Tragl, K.H., Hinterhuber, H., and Fischer, P. (2008). Effects of medications on plasma amyloid beta (Aβ) 42: longitudinal data from the VITA cohort. J. Psychiatr. Res. 42: 946–955, https://doi.org/10.1016/j.jpsychires.2007.10.010.Search in Google Scholar PubMed
Blom, D.J., Chen, J., Yuan, Z., Borges, J.L., Monsalvo, M.L., Wang, N., Hamer, A.W., and Ge, J. (2020). Effects of evolocumab therapy and low LDL‐C levels on vitamin E and steroid hormones in Chinese and global patients with type 2 diabetes. Endocrinol. Diabetes Metab J. 3: e00123, https://doi.org/10.1002/edm2.123.Search in Google Scholar PubMed PubMed Central
Bosco, D.A., Fowler, D.M., Zhang, Q., Nieva, J., Powers, E.T., Wentworth, P., Lerner, R.A., and Kelly, J.W. (2006). Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate α-synuclein fibrilization. Nat. Chem. Biol. 2: 249–253, https://doi.org/10.1038/nchembio782.Search in Google Scholar PubMed
Botta, M., Audano, M., Sahebkar, A., Sirtori, C.R., Mitro, N., and Ruscica, M. (2018). PPAR agonists and metabolic syndrome: an established role? Int. J. Mol. Sci. 19: 1197, https://doi.org/10.3390/ijms19041197.Search in Google Scholar PubMed PubMed Central
Carlsson, C.M., Gleason, C.E., Hess, T.M., Moreland, K.A., Blazel, H.M., Koscik, R.L., Schreiber, N.T., Johnson, S.C., Atwood, C.S., Puglielli, L., et al.. (2008). Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer’s disease. J. Alzheim. Dis. 13: 187–197, https://doi.org/10.3233/jad-2008-13209.Search in Google Scholar PubMed
Chaffman, M.O., Webster, W.B., and Winiecki, J.T. (2013). Efficacy and safety evaluation of a large niacin therapeutic interchange program. Ann. Pharmacother. 47: 657–664, https://doi.org/10.1345/aph.1r736.Search in Google Scholar
Chan, D., Binks, S., Nicholas, J.M., Frost, C., Cardoso, M.J., Ourselin, S., Wilkie, D., Nicholas, R., and Chataway, J. (2017). Effect of high-dose simvastatin on cognitive, neuropsychiatric, and health-related quality-of-life measures in secondary progressive multiple sclerosis: secondary analyses from the MS-STAT randomised, placebo-controlled trial. Lancet Neurol. 16: 591–600, https://doi.org/10.1016/s1474-4422(17)30113-8.Search in Google Scholar PubMed PubMed Central
Chang, Y.H., Yen, S.J., Chang, Y.H., Wu, W.J., and Lin, K.D. (2021). Pioglitazone and statins lower incidence of Parkinson disease in patients with diabetes mellitus. Eur. Neurol. 28: 430–437, https://doi.org/10.1111/ene.14542.Search in Google Scholar PubMed
Chataway, J., Schuerer, N., Alsanousi, A., Chan, D., MacManus, D., Hunter, K., Anderson, V., Bangham, C.R., Clegg, S., Nielsen, C., et al.. (2014). Effect of high-dose simvastatin on brain atrophy and disability in secondary progressive multiple sclerosis (MS-STAT): a randomised, placebo-controlled, phase 2 trial. Lancet 383: 2213–2221, https://doi.org/10.1016/s0140-6736(13)62242-4.Search in Google Scholar PubMed
Chen, F., Maccubbin, D., Yan, L., Sirah, W., Chen, E., Sisk, C.M., Davidson, M., Blomqvist, P., and McKenney, J.M. (2013). Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia. Int. J. Cardiol. 167: 225–231, https://doi.org/10.1016/j.ijcard.2011.12.103.Search in Google Scholar PubMed
Chiu, H.-F., Venkatakrishnan, K., and Wang, C.-K. (2020). The role of nutraceuticals as a complementary therapy against various neurodegenerative diseases: a mini-review. J. Tradit. Complement. Med. 10: 434–439, https://doi.org/10.1016/j.jtcme.2020.03.008.Search in Google Scholar PubMed PubMed Central
Chruściel, P., Sahebkar, A., Rembek-Wieliczko, M., Serban, M.C., Ursoniu, S., Mikhailidis, D.P., Jones, S.R., Mosteoru, S., Blaha, M.J., Martin, S.S., et al.. (2016). Impact of statin therapy on plasma adiponectin concentrations: a systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis 253: 194–208, https://doi.org/10.1016/j.atherosclerosis.2016.07.897.Search in Google Scholar PubMed
Cicero, A.F., Pontremoli, R., Fogacci, F., Viazzi, F., and Borghi, C. (2020). Effect of bempedoic acid on serum uric acid and related outcomes: a systematic review and meta-analysis of the available phase 2 and phase 3 clinical studies. Drug Saf. 43: 1–10, https://doi.org/10.1007/s40264-020-00931-6.Search in Google Scholar PubMed
Collaboration, P.S. (2007). Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370: 1829–1839, https://doi.org/10.1016/S0140-6736(07)61778-4.Search in Google Scholar PubMed
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G.D., DeMets, D., et al.. (2016). Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 388: 2532–2561, https://doi.org/10.1016/s0140-6736(16)31357-5.Search in Google Scholar PubMed
Courtemanche, H., Bigot, E., Pichelin, M., Guyomarch, B., Boutoleau-Bretonnière, C., Le May, C., Derkinderen, P., and Cariou, B. (2018). PCSK9 concentrations in cerebrospinal fluid are not specifically increased in Alzheimer’s disease. J. Alzheim. Dis. 62: 1519–1525, https://doi.org/10.3233/jad-170993.Search in Google Scholar
Culver, A.L., Ockene, I.S., Balasubramanian, R., Olendzki, B.C., Sepavich, D.M., Wactawski-Wende, J., Manson, J.E., Qiao, Y., Liu, S., and Merriam, P.A. (2012). Statin use and risk of diabetes mellitus in postmenopausal women in the Women’s Health Initiative. Arch. Intern. Med. 172: 144–152, https://doi.org/10.1001/archinternmed.2011.625.Search in Google Scholar PubMed
Davidson, M.H., Armani, A., McKenney, J.M., and Jacobson, T.A. (2007). Safety considerations with fibrate therapy. Am. J. Cardiol. 99: S3–S18, https://doi.org/10.1016/j.amjcard.2006.11.016.Search in Google Scholar PubMed
Davis, T., Yeap, B., Davis, W., and Bruce, D. (2008). Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 51: 562–566, https://doi.org/10.1007/s00125-007-0919-2.Search in Google Scholar PubMed
De Caterina, R., Salvatore, T., and Marchioli, R. (2016). Cholesterol-lowering interventions and stroke: insights from IMPROVE-IT. Atherosclerosis 248: 216–218, https://doi.org/10.1016/j.atherosclerosis.2016.03.024.Search in Google Scholar PubMed
Domanico, D., Verboschi, F., Altimari, S., Zompatori, L., and Vingolo, E.M. (2015). Ocular effects of niacin: a review of the literature. Med. Hypothesis, Discov. Innovation (MEHDI) Ophthalmol. 4: 64.Search in Google Scholar
Dunatchik, A.P., Ito, M.K., and Dujovne, C.A. (2012). A systematic review on evidence of the effectiveness and safety of a wax-matrix niacin formulation. J. Clin. Lipidol. 6: 121–131, https://doi.org/10.1016/j.jacl.2011.07.003.Search in Google Scholar PubMed
Elisaf, M., Florentin, M., Liberopoulos, E., and Mikhailidis, D. (2008). Fibrate-associated adverse effects beyond muscle and liver toxicity. Curr. Pharmaceut. Des. 14: 574, https://doi.org/10.2174/138161208783885362.Search in Google Scholar PubMed
Emmerich, K.-H., Poritis, N., Stelmane, I., Klindzane, M., Erbler, H., Goldsteine, J., and Görtelmeyer, R. (2009). Wirksamkeit und Sicherheit von Etofibrat bei Patienten mit nicht proliferativer diabetischer Retinopathie. Klin. Monatsbl. Augenheilkd. 226: 561–567, https://doi.org/10.1055/s-0028-1109516.Search in Google Scholar PubMed
Enger, C., Gately, R., Ming, E.E., Niemcryk, S.J., Williams, L., and McAfee, A.T. (2010). Pharmacoepidemiology safety study of fibrate and statin concomitant therapy. Am. J. Cardiol. 106: 1594–1601, https://doi.org/10.1016/j.amjcard.2010.07.041.Search in Google Scholar PubMed
Etminan, M., Samii, A., and Brophy, J.M. (2010). Statin use and risk of epilepsy: a nested case-control study. Neurology 75: 1496–1500, https://doi.org/10.1212/wnl.0b013e3181f96253.Search in Google Scholar
Fang, J., Tuo, M., Ouyang, K., and Xu, Y. (2021). Statin on post-stroke epilepsy: a systematic review and meta-analysis. J. Clin. Neurosci. 83: 83–87, https://doi.org/10.1016/j.jocn.2020.11.023.Search in Google Scholar PubMed
Farnier, M., Jones, P., Severance, R., Averna, M., Steinhagen-Thiessen, E., Colhoun, H.M., Du, Y., Hanotin, C., and Donahue, S. (2016). Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: the ODYSSEY OPTIONS II randomized trial. Atherosclerosis 244: 138–146, https://doi.org/10.1016/j.atherosclerosis.2015.11.010.Search in Google Scholar PubMed
Feldman, H., Doody, R., Kivipelto, M., Sparks, D., Waters, D., Jones, R., Schwam, E., Schindler, R., Hey-Hadavi, J., DeMicco, D., et al.. (2010). Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74: 956–964, https://doi.org/10.1212/wnl.0b013e3181d6476a.Search in Google Scholar
Ferretti, G., Bacchetti, T., and Sahebkar, A. (2015). Effect of statin therapy on paraoxonase-1 status: a systematic review and meta-analysis of 25 clinical trials. Prog. Lipid Res. 60: 50–73, https://doi.org/10.1016/j.plipres.2015.08.003.Search in Google Scholar PubMed
Floyd, C. and Crook, M. (2021). Adverse events to PCSK-9 inhibitors: what is the current evidence? Postgrad. Med. J. 97: 485–486.10.1136/postgradmedj-2020-138746Search in Google Scholar PubMed
Friedman, B., Lahad, A., Dresner, Y., and Vinker, S. (2013). Long-term statin use and the risk of Parkinson’s disease. Am. J. Manag. Care 19: 626–632.Search in Google Scholar
Fu, Y., Lin, X., Chen, Y.-J., Lai, L.-L., Lin, Y., Wang, M.-W., Lam, S.M., Zeng, Y.-H., Lin, X.-H., and Li, Y.-L. (2020). Evolocumab (PCSK9 inhibitor) in hereditary spastic paraplegia type 5.10.2139/ssrn.3569873Search in Google Scholar
Gagne, J.J., Houstoun, M., Reichman, M.E., Hampp, C., Marshall, J.H., and Toh, S. (2018). Safety assessment of niacin in the US food and drug administration’s mini‐sentinel system. Pharmacoepidemiol. Drug Saf. 27: 30–37, https://doi.org/10.1002/pds.4343.Search in Google Scholar PubMed
Gale, J. and Danesh-Meyer, H.V. (2014). Statins can induce myasthenia gravis. J. Clin. Neurosci. 21: 195–197, https://doi.org/10.1016/j.jocn.2013.11.009.Search in Google Scholar PubMed
Ganga, H.V., Slim, H.B., and Thompson, P.D. (2014). A systematic review of statin-induced muscle problems in clinical trials. Am. Heart J. 168: 6–15, https://doi.org/10.1016/j.ahj.2014.03.019.Search in Google Scholar PubMed
Garg, A., Sharma, A., Krishnamoorthy, P., Garg, J., Virmani, D., Sharma, T., Stefanini, G., Kostis, J.B., Mukherjee, D., and Sikorskaya, E. (2017). Role of niacin in current clinical practice: a systematic review. Am. J. Med. 130: 173–187, https://doi.org/10.1016/j.amjmed.2016.07.038.Search in Google Scholar PubMed
Geifman, N., Brinton, R.D., Kennedy, R.E., Schneider, L.S., and Butte, A.J. (2017). Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer’s disease. Alzheimer’s Res. Ther. 9: 1–10, https://doi.org/10.1186/s13195-017-0237-y.Search in Google Scholar PubMed PubMed Central
Gencer, B. and Mach, F. (2018). So low so far so good: neurocognitive impact of lowering LDL-C levels with PCSK9 inhibitors. Eur. Heart J. 39: 382–384, https://doi.org/10.1093/eurheartj/ehx742.Search in Google Scholar PubMed
Ghasami, K., Faraji, F., Fazeli, M., Ghazavi, A., and Mosayebi, G. (2016). Interferon β-1a and Atorvastatin in the treatment of multiple sclerosis. Iran. J Immunol 13: 16–26.Search in Google Scholar
Giral, P. (2020). Bempedoic acid to lower LDL cholesterol-safety and efficacy. N. Engl. J. Med. 383: e49, https://doi.org/10.1056/NEJMc1908495.Search in Google Scholar PubMed
Giugliano, R.P., Cannon, C.P., Blazing, M.A., Nicolau, J.C., Corbalán, R., Špinar, J., Park, J.-G., White, J.A., Bohula, E.A., and Braunwald, E. (2018). Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (improved reduction of outcomes: Vytorin efficacy international trial). Circulation 137: 1571–1582, https://doi.org/10.1161/circulationaha.117.030950.Search in Google Scholar
Giugliano, R.P., Mach, F., Zavitz, K., Kurtz, C., Im, K., Kanevsky, E., Schneider, J., Wang, H., Keech, A., and Pedersen, T.R. (2017). Cognitive function in a randomized trial of evolocumab. N. Engl. J. Med. 377: 633–643, https://doi.org/10.1056/nejmoa1701131.Search in Google Scholar PubMed
Goldfine, A., Fonseca, V., Jones, M., Wang, A., Ford, D., and Truitt, K. (2010). Long-term safety and tolerability of colesevelam HCl in subjects with type 2 diabetes. Horm. Metab. Res. 42: 23–30, https://doi.org/10.1055/s-0029-1241195.Search in Google Scholar PubMed
Goldie, C., Taylor, A.J., Nguyen, P., McCoy, C., Zhao, X.-Q., and Preiss, D. (2016). Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials. Heart 102: 198–203, https://doi.org/10.1136/heartjnl-2015-308055.Search in Google Scholar PubMed PubMed Central
Group, H.-T.C. (2014). Effects of extended-release niacin with laropiprant in high-risk patients. N. Engl. J. Med. 371: 203–212, https://doi.org/10.1056/nejmoa1300955.Search in Google Scholar
Guedeney, P., Giustino, G., Sorrentino, S., Claessen, B.E., Camaj, A., Kalkman, D.N., Vogel, B., Sartori, S., De Rosa, S., and Baber, U. (2019). Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials. Eur. Heart J., https://doi.org/10.1093/eurheartj/ehz430.Search in Google Scholar PubMed
Gürgöze, M.T., Muller‐Hansma, A.H., Schreuder, M.M., Galema‐Boers, A.M., Boersma, E., and Roeters van Lennep, J.E. (2019). Adverse events associated with PCSK 9 inhibitors: a real‐world experience. Clin. Pharmacol Ther. 105: 496–504, https://doi.org/10.1002/cpt.1193.Search in Google Scholar PubMed PubMed Central
Haag, M.D., Hofman, A., Koudstaal, P.J., Stricker, B.H., and Breteler, M.M. (2009). Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity the Rotterdam Study. J. Neurol. Neurosurg. Psychiatry 80: 13–17, https://doi.org/10.1136/jnnp.2008.150433.Search in Google Scholar PubMed
Han, Y., Chen, J., Chopra, V.K., Zhang, S., Su, G., Ma, C., Huang, Z., Ma, Y., Yao, Z., and Yuan, Z. (2020). ODYSSEY EAST: alirocumab efficacy and safety vs. ezetimibe in high cardiovascular risk patients with hypercholesterolemia and on maximally tolerated statin in China, India, and Thailand. J. Clin. Lipidol. 14: 98–108, https://doi.org/10.1016/j.jacl.2019.10.015.Search in Google Scholar PubMed
Hansen, M., Sonne, D.P., Mikkelsen, K.H., Gluud, L.L., Vilsbøll, T., and Knop, F.K. (2017). Bile acid sequestrants for glycemic control in patients with type 2 diabetes: a systematic review with meta-analysis of randomized controlled trials. J. Diabetes Complicat. 31: 918–927, https://doi.org/10.1016/j.jdiacomp.2017.01.011.Search in Google Scholar PubMed
Harvey, P.D., Sabbagh, M.N., Harrison, J.E., Ginsberg, H.N., Chapman, M.J., Manvelian, G., Moryusef, A., Mandel, J., and Farnier, M. (2018). No evidence of neurocognitive adverse events associated with alirocumab treatment in 3340 patients from 14 randomized Phase 2 and 3 controlled trials: a meta-analysis of individual patient data. Eur. Heart J. 39: 374–381, https://doi.org/10.1093/eurheartj/ehx661.Search in Google Scholar PubMed PubMed Central
Haynes, R., Valdes-Marquez, E., Hopewell, J.C., Chen, F., Li, J., Parish, S., Landray, M.J., Armitage, J., Collins, R., and Armitage, J. (2019). Serious adverse effects of extended-release niacin/laropiprant: results from the Heart protection study 2–treatment of HDL to reduce the incidence of vascular events (HPS2-THRIVE) trial. Clin. Therapeut. 41: 1767–1777, https://doi.org/10.1016/j.clinthera.2019.06.012.Search in Google Scholar PubMed
Hippisley-Cox, J. and Coupland, C. (2010). Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. Br. Med. J. 340: c2197, https://doi.org/10.1136/bmj.c2197.Search in Google Scholar PubMed PubMed Central
Holbrook, A., Wright, M., Sung, M., Ribic, C., and Baker, S. (2011). Statin-associated rhabdomyolysis: is there a dose-response relationship? Can. J. Cardiol. 27: 146–151, https://doi.org/10.1016/j.cjca.2010.12.024.Search in Google Scholar PubMed
Holoshitz, N., Alsheikh-Ali, A.A., and Karas, R.H. (2008). Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use. Am. J. Cardiol. 101: 95–97, https://doi.org/10.1016/j.amjcard.2007.07.057.Search in Google Scholar PubMed
Huang, X., Chen, H., Miller, W.C., Mailman, R.B., Woodard, J.L., Chen, P.C., Xiang, D., Murrow, R.W., Wang, Y.Z., and Poole, C. (2007). Lower low‐density lipoprotein cholesterol levels are associated with Parkinson’s disease. Mov. Disord. 22: 377–381, https://doi.org/10.1002/mds.21290.Search in Google Scholar PubMed PubMed Central
Ida, S., Kaneko, R., and Murata, K. (2019). Efficacy and safety of pemafibrate administration in patients with dyslipidemia: a systematic review and meta-analysis. Cardiovasc. Diabetol. 18: 1–14, https://doi.org/10.1186/s12933-019-0845-x.Search in Google Scholar PubMed PubMed Central
Jeong, S.M., Jang, W., and Shin, D.W. (2019). Association of statin use with Parkinson’s disease: dose–response relationship. Mov. Disord. 34: 1014–1021, https://doi.org/10.1002/mds.27681.Search in Google Scholar PubMed
Jones, P.H., Bays, H.E., Chaudhari, U., Pordy, R., Lorenzato, C., Miller, K., and Robinson, J.G. (2016). Safety of alirocumab (a PCSK9 monoclonal antibody) from 14 randomized trials. Am. J. Cardiol. 118: 1805–1811, https://doi.org/10.1016/j.amjcard.2016.08.072.Search in Google Scholar PubMed
Jukema, J.W., Zijlstra, L.E., Bhatt, D.L., Bittner, V.A., Diaz, R., Drexel, H., Goodman, S.G., Kim, Y.-U., Pordy, R., and Reiner, Ž. (2019). Effect of alirocumab on stroke in ODYSSEY OUTCOMES. Circulation 140: 2054–2062, https://doi.org/10.1161/circulationaha.119.043826.Search in Google Scholar PubMed PubMed Central
Jun, M., Zhu, B., Tonelli, M., Jardine, M.J., Patel, A., Neal, B., Liyanage, T., Keech, A., Cass, A., and Perkovic, V. (2012). Effects of fibrates in kidney disease: a systematic review and meta-analysis. J. Am. Coll. Cardiol. 60: 2061–2071, https://doi.org/10.1016/j.jacc.2012.07.049.Search in Google Scholar PubMed
Kamm, C.P., El-Koussy, M., Humpert, S., Findling, O., Burren, Y., Schwegler, G., Donati, F., Müller, M., Müller, F., and Slotboom, J. (2014). Atorvastatin added to interferon beta for relapsing multiple sclerosis: 12-month treatment extension of the randomized multicenter SWABIMS trial. PLoS One 9: e86663, https://doi.org/10.1371/journal.pone.0086663.Search in Google Scholar PubMed PubMed Central
Kamm, C.P. and Mattle, H.P. (2009). Swiss atorvastatin and interferon beta-1b trial in multiple sclerosis (SWABIMS)-rationale, design and methodology. Trials 10: 1–7, https://doi.org/10.1186/1745-6215-10-115.Search in Google Scholar PubMed PubMed Central
Kandelouei, T., Abbasifard, M., Imani, D., Aslani, S., Razi, B., Fasihi, M., Shafiekhani, S., Mohammadi, K., Jamialahmadi, T., Reiner, Z., et al.. (2022). Effect of statins on serum level of hs-CRP and CRP in patients with cardiovascular diseases: a systematic review and meta-analysis of randomized controlled trials. Mediat. Inflamm. 2022: 8732360, https://doi.org/10.5114/aoms.2020.100304.Search in Google Scholar PubMed PubMed Central
Kastelein, J.J., Akdim, F., Stroes, E.S., Zwinderman, A.H., Bots, M.L., Stalenhoef, A.F., Visseren, F.L., Sijbrands, E.J., Trip, M.D., and Stein, E.A. (2008). Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358: 1431–1443, https://doi.org/10.1056/nejmoa0800742.Search in Google Scholar
Katsanos, A.H., Lioutas, V.-A., Charidimou, A., Catanese, L., Ng, K.K.H., Perera, K., de Sa Boasquevisque, D., Falcone, G.J., Sheth, K.N., and Romero, J.R. (2020). Statin treatment and cerebral microbleeds: a systematic review and meta-analysis. J. Neurol. Sci. 420: 117224, https://doi.org/10.1016/j.jns.2020.117224.Search in Google Scholar PubMed
Keech, A.C., Mitchell, P., Summanen, P., O’Day, J., Davis, T.M., Moffitt, M., Taskinen, M.-R., Simes, R.J., Tse, D., and Williamson, E. (2007). Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 370: 1687–1697, https://doi.org/10.1016/s0140-6736(07)61607-9.Search in Google Scholar
Kereiakes, D.J., Robinson, J.G., Cannon, C.P., Lorenzato, C., Pordy, R., Chaudhari, U., and Colhoun, H.M. (2015). Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: the ODYSSEY COMBO I study. Am. Heart J. 169: 906–915, https://doi.org/10.1016/j.ahj.2015.03.004.Search in Google Scholar PubMed
Khan, A.R., Bavishi, C., Riaz, H., Farid, T.A., Khan, S., Atlas, M., Hirsch, G., Ikram, S., and Bolli, R. (2017). Increased risk of adverse neurocognitive outcomes with proprotein convertase subtilisin-kexin type 9 inhibitors. Circulation 10: e003153, https://doi.org/10.1161/circoutcomes.116.003153.Search in Google Scholar PubMed
Koslik, H.J., Meskimen, A.H., and Golomb, B.A. (2017). Physicians’ experiences as patients with statin side effects: a case series. Drug. Saf. Case Rep. 4: 3, https://doi.org/10.1007/s40800-017-0045-0.Search in Google Scholar PubMed PubMed Central
Koushki, K., Shahbaz, S.K., Mashayekhi, K., Sadeghi, M., Zayeri, Z.D., Taba, M.Y., Banach, M., Al-Rasadi, K., Johnston, T.P., and Sahebkar, A. (2021). Anti-inflammatory action of statins in cardiovascular disease: the role of inflammasome and toll-like receptor pathways. Clin. Rev. Allergy Immunol. 60: 175–199, https://doi.org/10.1007/s12016-020-08791-9.Search in Google Scholar PubMed PubMed Central
Lambert, G., Sjouke, B., Choque, B., Kastelein, J.J., and Hovingh, G.K. (2012). The PCSK9 decade: thematic review series: new lipid and lipoprotein targets for the treatment of cardiometabolic diseases. J. Lipid Res. 53: 2515–2524, https://doi.org/10.1194/jlr.r026658.Search in Google Scholar
Lanzillo, R., Orefice, G., Quarantelli, M., Rinaldi, C., Prinster, A., Ventrella, G., Spitaleri, D., Lus, G., Vacca, G., and Carotenuto, B. (2010). Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing—remitting active multiple sclerosis patients: a longitudinal controlled trial of combination therapy. Mult. Scler. Int. 16: 450–454, https://doi.org/10.1177/1352458509358909.Search in Google Scholar PubMed
Lanzillo, R., Quarantelli, M., Pozzilli, C., Trojano, M., Amato, M.P., Marrosu, M.G., Francia, A., Florio, C., Orefice, G., and Tedeschi, G. (2016). No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing–remitting multiple sclerosis (the ARIANNA study). Mult. Scler. Int. 22: 1163–1173, https://doi.org/10.1177/1352458515611222.Search in Google Scholar PubMed
Laufs, U., Banach, M., Mancini, G.J., Gaudet, D., Bloedon, L.T., Sterling, L.R., Kelly, S., and Stroes, E.S. (2019). Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J. Am. Heart Assoc. 8: e011662, https://doi.org/10.1161/jaha.118.011662.Search in Google Scholar PubMed PubMed Central
Lee, J.W., Choi, E.A., Kim, Y.S., Kim, Y., You, H.S., Han, Y.E., Kim, H.S., Bae, Y.J., Kim, J., and Kang, H.T. (2020). Statin exposure and the risk of dementia in individuals with hypercholesterolaemia. J. Intern. Med. 288: 689–698, https://doi.org/10.1111/joim.13134.Search in Google Scholar PubMed
Lehrer, S. and Rheinstein, P.H. (2020). Statins combined with niacin reduce the risk of peripheral neuropathy. Int. J. Funct. Nutr. 1: 1, https://doi.org/10.3892/ijfn.2020.3.Search in Google Scholar PubMed PubMed Central
Levy, P. (2010). Review of studies on the effect of bile acid sequestrants in patients with type 2 diabetes mellitus. Metab. Syndr. Relat. Disord. 8: S-9–S-13, https://doi.org/10.1089/met.2010.0087.Search in Google Scholar PubMed
Li, G., Larson, E., Sonnen, J., Shofer, J., Petrie, E., Schantz, A., Peskind, E., Raskind, M., Breitner, J., and Montine, T. (2007). Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 69: 878–885, https://doi.org/10.1212/01.wnl.0000277657.95487.1c.Search in Google Scholar PubMed
Li, X.-l., Zhang, Z.-c., Zhang, B., Jiang, H., Yu, C.-m., Zhang, W.-j., Yan, X., and Wang, M.-x. (2014). Atorvastatin calcium in combination with methylprednisolone for the treatment of multiple sclerosis relapse. Int. Immunopharm. 23: 546–549, https://doi.org/10.1016/j.intimp.2014.10.004.Search in Google Scholar PubMed
Lomas-Lee, M., Bocanegra-García, V., Ordaz-Pichardo, C., González, J., and Rivera, G. (2009). Effect of statins and fibrates on plasma creatine phosphokinase in Mexican patients with hypercholesterolemia. Bioquimia 34: 21–25.Search in Google Scholar
Lovadi, E., Csécsei, P., Lovig, C., Karádi, Z., and Szapáry, L. (2016). Lipidek és az agyérbetegség–Új lehetőségek az LDL-koleszterin-szint csökkentésére. Orv. Hetil. 157: 2059–2065, https://doi.org/10.1556/650.2016.30643.Search in Google Scholar PubMed
Macedo, A.F., Taylor, F.C., Casas, J.P., Adler, A., Prieto-Merino, D., and Ebrahim, S. (2014). Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis. BMC Med. 12: 1–13, https://doi.org/10.1186/1741-7015-12-51.Search in Google Scholar PubMed PubMed Central
Mahboobnia, K., Pirro, M., Marini, E., Grignani, F., Bezsonov, E.E., Jamialahmadi, T., and Sahebkar, A. (2021). PCSK9 and cancer: rethinking the link. Biomed. Pharmacother. 140: 111758, https://doi.org/10.1016/j.biopha.2021.111758.Search in Google Scholar PubMed
Matsubara, S., Tanaka, T., Tomari, S., Fukuma, K., Ishiyama, H., Abe, S., Arimizu, T., Yamaguchi, Y., Ogata, S., and Nishimura, K. (2020). Statin treatment can reduce incidence of early seizure in acute ischemic stroke: a propensity score analysis. Sci. Rep. 10: 1–7, https://doi.org/10.1038/s41598-020-58652-w.Search in Google Scholar PubMed PubMed Central
McGuinness, B., O’Hare, J., Craig, D., Bullock, R., Malouf, R., and Passmore, P. (2013). Cochrane review on ‘Statins for the treatment of dementia’. Int. J. Geriatr. Psychiatr. 28: 119–126, https://doi.org/10.1002/gps.3797.Search in Google Scholar PubMed
Miao, X., Liu, H., Jin, M., Sun, B., Tian, H., Li, J., Li, N., and Yan, S. (2019). A comparative meta-analysis of the efficacy of statin–ezetimibe co-therapy versus statin monotherapy in reducing cardiovascular and cerebrovascular adverse events in patients with type 2 diabetes mellitus. Eur. Rev. Med. Pharmacol. Sci. 23: 2302–2310, https://doi.org/10.26355/eurrev_201903_17279.Search in Google Scholar PubMed
Molero, Y., Cipriani, A., Larsson, H., Lichtenstein, P., D’Onofrio, B.M., and Fazel, S. (2020). Associations between statin use and suicidality, depression, anxiety, and seizures: a Swedish total-population cohort study. Lancet Psychiatr. 7: 982–990, https://doi.org/10.1016/s2215-0366(20)30311-4.Search in Google Scholar PubMed PubMed Central
Montaner, J., Bustamante, A., García-Matas, S., Martínez-Zabaleta, M., Jiménez, C., De La Torre, J., Rubio, F.R., Segura, T., Masjuán, J., and Cánovas, D. (2016). Combination of thrombolysis and statins in acute stroke is safe: results of the STARS randomized trial (stroke treatment with acute reperfusion and simvastatin). Stroke 47: 2870–2873, https://doi.org/10.1161/strokeaha.116.014600.Search in Google Scholar
Montaner, J., Chacón, P., Krupinski, J., Rubio, F., Millán, M., Molina, C., Hereu, P., Quintana, M., and Alvarez‐Sabín, J. (2008). Simvastatin in the acute phase of ischemic stroke: a safety and efficacy pilot trial. Eur. Neurol. 15: 82–90, https://doi.org/10.1111/j.1468-1331.2007.02015.x.Search in Google Scholar PubMed
Moran, E.P. and Ma, J.-x. (2015). Therapeutic effects of PPARα on neuronal death and microvascular impairment. PPAR Res. 2015: 595426, https://doi.org/10.1155/2015/595426.Search in Google Scholar PubMed PubMed Central
Moriarty, P.M., Jacobson, T.A., Bruckert, E., Thompson, P.D., Guyton, J.R., Baccara-Dinet, M.T., and Gipe, D. (2014). Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. J. Clin. Lipidol. 8: 554–561, https://doi.org/10.1016/j.jacl.2014.09.007.Search in Google Scholar PubMed
Mutez, E., Duhamel, A., Defebvre, L., Bordet, R., Destée, A., and Kreisler, A. (2009). Lipid-lowering drugs are associated with delayed onset and slower course of Parkinson’s disease. Pharmacol. Res. 60: 41–45, https://doi.org/10.1016/j.phrs.2009.03.010.Search in Google Scholar PubMed
Nassief, A. and Marsh, J.D. (2008). Statin therapy for stroke prevention. Stroke 39: 1042–1048, https://doi.org/10.1161/strokeaha.107.501361.Search in Google Scholar PubMed
Niman, S., Rana, K., Reid, J., Sheikh-Ali, M., Lewis, T., Choksi, R.R., and Goldfaden, R.F. (2020). A review of the efficacy and tolerability of bempedoic acid in the treatment of hypercholesterolemia. Am. J. Cardiovasc. 20: 1–14.10.1007/s40256-020-00399-wSearch in Google Scholar PubMed
Nucera, B., Rinaldi, F., Nardone, R., Lattanzi, S., and Brigo, F. (2020). Statins in primary prevention of poststroke seizures and epilepsy: a systematic review. Epilepsy Behav. 112: 107400, https://doi.org/10.1016/j.yebeh.2020.107400.Search in Google Scholar PubMed
Oikawa, S., Yamashita, S., Nakaya, N., Sasaki, J., and Kono, S. (2016). Efficacy and safety of long-term coadministration of fenofibrate and ezetimibe in patients with combined hyperlipidemia: results of the EFECTL study. J. Atherosclerosis Thromb. 24: 35626.10.26226/morressier.571f103ed462b8028d88c4faSearch in Google Scholar
Okopień, B., Bułdak, Ł., and Bołdys, A. (2018). Benefits and risks of the treatment with fibrates––a comprehensive summary. Expet Rev. Clin. Pharmacol. 11: 1099–1112, https://doi.org/10.1080/17512433.2018.1537780.Search in Google Scholar PubMed
Paquette, M., Saavedra, Y.G.L., Poirier, J., Théroux, L., Dea, D., Baass, A., and Dufour, R. (2018). Loss-of-function PCSK9 mutations are not associated with Alzheimer disease. J. Geriatr. Psychiatr. Neurol. 31: 90–96, https://doi.org/10.1177/0891988718764330.Search in Google Scholar PubMed
Parizadeh, S.M.R., Azarpazhooh, M.R., Moohebati, M., Nematy, M., Ghayour-Mobarhan, M., Tavallaie, S., Rahsepar, A.A., Amini, M., Sahebkar, A., Mohammadi, M., et al.. (2011). Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial. Lipids 46: 333–340, https://doi.org/10.1007/s11745-010-3517-x.Search in Google Scholar PubMed
Parker, B.A., Capizzi, J.A., Grimaldi, A.S., Clarkson, P.M., Cole, S.M., Keadle, J., Chipkin, S., Pescatello, L.S., Simpson, K., and White, C.M. (2013). Effect of statins on skeletal muscle function. Circulation 127: 96–103, https://doi.org/10.1161/circulationaha.112.136101.Search in Google Scholar
Paul, F., Waiczies, S., Wuerfel, J., Bellmann-Strobl, J., Dörr, J., Waiczies, H., Haertle, M., Wernecke, K.D., Volk, H.-D., and Aktas, O. (2008). Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS One 3: e1928, https://doi.org/10.1371/journal.pone.0001928.Search in Google Scholar PubMed PubMed Central
Paul, R., Choudhury, A., and Borah, A. (2015). Cholesterol–a putative endogenous contributor towards Parkinson’s disease. Neurochem. Int. 90: 125–133, https://doi.org/10.1016/j.neuint.2015.07.025.Search in Google Scholar PubMed
Pihl-Jensen, G., Tsakiri, A., and Frederiksen, J.L. (2015). Statin treatment in multiple sclerosis: a systematic review and meta-analysis. CNS Drugs 29: 277–291, https://doi.org/10.1007/s40263-015-0239-x.Search in Google Scholar PubMed
Pirillo, A. and Catapano, A.L. (2022). New insights into the role of bempedoic acid and ezetimibe in the treatment of hypercholesterolemia. Curr. Opin. Endocrinol. Diabetes Obes. 29: 161, https://doi.org/10.1097/med.0000000000000706.Search in Google Scholar
Podbielska, M., O’Keeffe, J., and Pokryszko-Dragan, A. (2021). New insights into multiple sclerosis mechanisms: lipids on the track to control inflammation and neurodegeneration. Int. J. Mol. Sci. 22: 7319, https://doi.org/10.3390/ijms22147319.Search in Google Scholar PubMed PubMed Central
Pugh, M.J.V., Knoefel, J.E., Mortensen, E.M., Amuan, M.E., Berlowitz, D.R., and Van Cott, A.C. (2009). New‐onset epilepsy risk factors in older veterans. J. Am. Geriatr. Soc. 57: 237–242, https://doi.org/10.1111/j.1532-5415.2008.02124.x.Search in Google Scholar PubMed
Rajamani, K., Colman, P.G., Li, L.P., Best, J.D., Voysey, M., D’Emden, M.C., Laakso, M., Baker, J.R., Keech, A.C., and Investigators, F.S. (2009). Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 373: 1780–1788, https://doi.org/10.1016/s0140-6736(09)60698-x.Search in Google Scholar PubMed PubMed Central
Ramsey, L.B., Johnson, S.G., Caudle, K.E., Haidar, C.E., Voora, D., Wilke, R.A., Maxwell, W.D., McLeod, H.L., Krauss, R.M., and Roden, D.M. (2014). The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin‐induced myopathy: 2014 update. Clin. Pharmacol Ther. 96: 423–428, https://doi.org/10.1038/clpt.2014.125.Search in Google Scholar PubMed PubMed Central
Ray, K.K., Bays, H.E., Catapano, A.L., Lalwani, N.D., Bloedon, L.T., Sterling, L.R., Robinson, P.L., and Ballantyne, C.M. (2019). Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N. Engl. J. Med. 380: 1022–1032, https://doi.org/10.1056/nejmoa1803917.Search in Google Scholar PubMed
Rekatsina, M., Paladini, A., Piroli, A., Zis, P., Pergolizzi, J.V., and Varrassi, G. (2020). Pathophysiology and therapeutic perspectives of oxidative stress and neurodegenerative diseases: a narrative review. Adv. Ther. 37: 113–139, https://doi.org/10.1007/s12325-019-01148-5.Search in Google Scholar PubMed PubMed Central
Ridker, P.M., Tardif, J.-C., Amarenco, P., Duggan, W., Glynn, R.J., Jukema, J.W., Kastelein, J.J., Kim, A.M., Koenig, W., and Nissen, S. (2017). Lipid-reduction variability and antidrug-antibody formation with bococizumab. N. Engl. J. Med. 376: 1517–1526, https://doi.org/10.1056/nejmoa1614062.Search in Google Scholar
Robinson, J.G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E.S., Langslet, G., Raal, F.J., and El Shahawy, M. (2015). Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372: 1489–1499, https://doi.org/10.1056/nejmoa1501031.Search in Google Scholar PubMed
Rosenson, R.S., Jacobson, T.A., Preiss, D., Djedjos, C.S., Dent, R., Bridges, I., and Miller, M. (2016). Efficacy and safety of the PCSK9 inhibitor evolocumab in patients with mixed hyperlipidemia. Cardiovasc. Drugs Ther. 30: 305–313, https://doi.org/10.1007/s10557-016-6666-1.Search in Google Scholar PubMed PubMed Central
Rossebø, A.B., Pedersen, T.R., Boman, K., Brudi, P., Chambers, J.B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., and Kesäniemi, Y.A. (2008). Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N. Engl. J. Med. 359: 1343–1356, https://doi.org/10.1056/nejmoa0804602.Search in Google Scholar
Rubino, J., MacDougall, D., E., Sterling, L., R., Hanselman, J., C., and Nicolls, S., J. (2021). Combination of bempedonic acid, ezetimib, and atorvastatin in hyperlipidemic patients, a randomized clinical trial. Atheroclerosis 320: 122–128, https://doi.org/10.1016/j.atherosclerosis.2020.12.023.Search in Google Scholar PubMed
Sabatine, M.S., Giugliano, R.P., Keech, A.C., Honarpour, N., Wiviott, S.D., Murphy, S.A., Kuder, J.F., Wang, H., Liu, T., and Wasserman, S.M. (2017). Evolocumab and clinical outcomes in patients with cardiovascular disease. N. Engl. J. Med. 376: 1713–1722, https://doi.org/10.1056/nejmoa1615664.Search in Google Scholar
Sabatine, M.S., Giugliano, R.P., Wiviott, S.D., Raal, F.J., Blom, D.J., Robinson, J., Ballantyne, C.M., Somaratne, R., Legg, J., and Wasserman, S.M. (2015). Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 372: 1500–1509, https://doi.org/10.1056/nejmoa1500858.Search in Google Scholar PubMed
Saeedi, R., Johns, K., Frohlich, J., Bennett, M.T., and Bondy, G. (2015). Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients. Lipids Health Dis. 14: 1–8, https://doi.org/10.1186/s12944-015-0054-x.Search in Google Scholar PubMed PubMed Central
Sahebkar, A., Kotani, K., Serban, C., Ursoniu, S., Mikhailidis, D.P., Jones, S.R., Ray, K.K., Blaha, M.J., Rysz, J., Toth, P.P., et al.. (2015a). Statin therapy reduces plasma endothelin-1 concentrations: a meta-analysis of 15 randomized controlled trials. Atherosclerosis 241: 433–442, https://doi.org/10.1016/j.atherosclerosis.2015.04.046.Search in Google Scholar
Sahebkar, A., Serban, C., Mikhailidis, D.P., Undas, A., Lip, G.Y.H., Muntner, P., Bittner, V., Ray, K.K., Watts, G.F., Hovingh, G.K., et al.. (2015b). Association between statin use and plasma d-dimer levels: a systematic review and meta-analysis of randomised controlled trials. Thromb. Haemostasis 114: 546–557, https://doi.org/10.1160/th14-11-0937.Search in Google Scholar
Salvatore, T., Morganti, R., Marchioli, R., and De Caterina, R. (2020). Cholesterol lowering and stroke: No longer room for pleiotropic effects of statins–confirmation from PCSK9 inhibitor studies. Am. J. Med. 133: 95–99, https://doi.org/10.1016/j.amjmed.2019.06.029.Search in Google Scholar PubMed
Sano, M., Bell, K., Galasko, D., Galvin, J., Thomas, R., Van Dyck, C., and Aisen, P. (2011). A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 77: 556–563, https://doi.org/10.1212/wnl.0b013e318228bf11.Search in Google Scholar
Santa-Cecília, F.V., Leite, C.A., Del-Bel, E., and Raisman-Vozari, R. (2019). The neuroprotective effect of doxycycline on neurodegenerative diseases. Neurotox. Res. 35: 981–986, https://doi.org/10.1007/s12640-019-00015-z.Search in Google Scholar PubMed
Schwartz, G.G., Steg, P.G., Szarek, M., Bhatt, D.L., Bittner, V.A., Diaz, R., Edelberg, J.M., Goodman, S.G., Hanotin, C., and Harrington, R.A. (2018). Alirocumab and cardiovascular outcomes after acute coronary syndrome. N. Engl. J. Med. 379: 2097–2107, https://doi.org/10.1056/nejmoa1801174.Search in Google Scholar
Sharma, P., Timilsina, B., Adhikari, J., Parajuli, P., Dhital, R., and Tachamo, N. (2019). Statin-induced necrotizing autoimmune myopathy: an extremely rare adverse effect from statin use. J. Community Hosp. Intern. Med. Perspect. 9: 503–506, https://doi.org/10.1080/20009666.2019.1702272.Search in Google Scholar PubMed PubMed Central
Sheng, Z., Jia, X., and Kang, M. (2016). Statin use and risk of Parkinson’s disease: a meta-analysis. Behav. Brain Res. 309: 29–34, https://doi.org/10.1016/j.bbr.2016.04.046.Search in Google Scholar PubMed
Shi, R., Zhao, L., and Qi, Y. (2018). The effect of fenofibrate on early retinal nerve fiber layer loss in type 2 diabetic patients: a case-control study. BMC Ophthalmol. 18: 1–7, https://doi.org/10.1186/s12886-018-0769-3.Search in Google Scholar PubMed PubMed Central
Sohrevardi, S.M., Nasab, F.S., Mirjalili, M.R., Bagherniya, M., Tafti, A.D., Jarrahzadeh, M.H., Azarpazhooh, M.R., Saeidmanesh, M., Banach, M., Jamialahmadi, T., et al.. (2021). Effect of atorvastatin on delirium status of patients in the intensive care unit: a randomized controlled trial. Arch. Med. Sci. 17: 1423, https://doi.org/10.5114/aoms.2019.89330.Search in Google Scholar PubMed PubMed Central
Sparks, D.L., Kryscio, R.J., Sabbagh, M.N., Connor, D.J., Sparks, L.M., and Liebsack, C. (2008). Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr. Alzheimer Res. 5: 416–421, https://doi.org/10.2174/156720508785132316.Search in Google Scholar PubMed
Spence, J.D. (2015). Statins and cataracts: reverse causality? Can. J. Cardiol. 31: 691, https://doi.org/10.1016/j.cjca.2014.12.018.Search in Google Scholar PubMed
Su, X., Zhang, L., Lv, J., Wang, J., Hou, W., Xie, X., and Zhang, H. (2016). Effect of statins on kidney disease outcomes: a systematic review and meta-analysis. Am. J. Kidney Dis. 67: 881–892, https://doi.org/10.1053/j.ajkd.2016.01.016.Search in Google Scholar PubMed
Swan, A.M., Thant, H.L., Chai, C.P.M., Khaing, H.H., Thein, M.Z., Lei, Y.W., and Thuzar, M. (2020). Clinical improvement in a patient with Parkinson’s disease and vascular dementia receiving PCSK9 inhibitor for ischemic heart disease: a case report.Search in Google Scholar
Swiger, K.J., Manalac, R.J., Blumenthal, R.S., Blaha, M.J., and Martin, S.S. (2013). Statins and cognition: a systematic review and meta-analysis of short-and long-term cognitive effects. Mayo Clin. Proc. 88: 1213–1221, https://doi.org/10.1016/j.mayocp.2013.07.013.Search in Google Scholar PubMed
Takeshita, Y., Takamura, T., Honda, M., Kita, Y., Zen, Y., Kato, K.-i., Misu, H., Ota, T., Nakamura, M., and Yamada, K. (2014). The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: a randomised controlled trial. Diabetologia 57: 878–890, https://doi.org/10.1007/s00125-013-3149-9.Search in Google Scholar PubMed
Thermos, G. and Tosios, K.I. (2019). Gingival ischemia and petechiae in a patient medicated with PCSK9 inhibitor for hypercholesterolemia: an adverse drug event? Clin. Adv. Periodontics 9: 20–23, https://doi.org/10.1002/cap.10043.Search in Google Scholar PubMed
Tison, F., Nègre-Pagès, L., Meissner, W.G., Dupouy, S., Li, Q., Thiolat, M.-L., Thiollier, T., Galitzky, M., Ory-Magne, F., and Milhet, A. (2013). Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over (“n-of-1”) exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson’s disease patients. Parkinsonism Relat. Disorders 19: 416–421, https://doi.org/10.1016/j.parkreldis.2012.12.003.Search in Google Scholar PubMed
Togha, M., Karvigh, S.A., Nabavi, M., Moghadam, N.B., Harirchian, M.H., Sahraian, M.A., Enzevaei, A., Nourian, A., Ghanaati, H., and Firouznia, K. (2010). Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Mult. Scler. Int. 16: 848–854, https://doi.org/10.1177/1352458510369147.Search in Google Scholar PubMed
Toth, P., Morrone, D., Weintraub, W., Hanson, M., Lowe, R., Lin, J., Shah, A., and Tershakovec, A. (2012). Safety profile of statins alone or combined with ezetimibe: a pooled analysis of 27 studies including over 22,000 patients treated for 6–24 weeks. Int. J. Clin. Pract. 66: 800–812, https://doi.org/10.1111/j.1742-1241.2012.02964.x.Search in Google Scholar PubMed
Trialists, C.T. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 376: 1670–1681, https://doi.org/10.1016/s0140-6736(10)61350-5.Search in Google Scholar PubMed PubMed Central
Trompet, S., van Vliet, P., de Craen, A.J., Jolles, J., Buckley, B.M., Murphy, M.B., Ford, I., Macfarlane, P.W., Sattar, N., and Packard, C.J. (2010). Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J. Neurol. 257: 85–90, https://doi.org/10.1007/s00415-009-5271-7.Search in Google Scholar PubMed
Tziomalos, K., Giampatzis, V., Bouziana, S.D., Spanou, M., Kostaki, S., Papadopoulou, M., Angelopoulou, S.-M., Konstantara, F., Savopoulos, C., and Hatzitolios, A.I. (2015). Comparative effects of more versus less aggressive treatment with statins on the long-term outcome of patients with acute ischemic stroke. Atherosclerosis 243: 65–70, https://doi.org/10.1016/j.atherosclerosis.2015.08.043.Search in Google Scholar PubMed
Ueshima, K., Itoh, H., Kanazawa, N., Komuro, I., Nagai, R., Takeuchi, M., Yamazaki, T., and group, E.s. (2016). Rationale and design of the standard versus intensive statin therapy for hypercholesterolemic patients with diabetic retinopathy (EMPATHY) study: a randomized controlled trial. J. Atherosclerosis Thromb. 23: 33563, https://doi.org/10.5551/jat.33563.Search in Google Scholar PubMed PubMed Central
Vahedian-Azimi, A., Mohammadi, S.M., Banach, M., Beni, F.H., Guest, P.C., Al-Rasadi, K., Jamialahmadi, T., and Sahebkar, A. (2021). Improved COVID-19 outcomes following statin therapy: an updated systematic review and meta-analysis. BioMed Res. Int. 1901772, https://doi.org/10.1155/2021/1901772.Search in Google Scholar PubMed PubMed Central
van der Graaf, A., Cuffie-Jackson, C., Vissers, M.N., Trip, M.D., Gagné, C., Shi, G., Veltri, E., Avis, H.J., and Kastelein, J.J. (2008). Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J. Am. Coll. Cardiol. 52: 1421–1429, https://doi.org/10.1016/j.jacc.2008.09.002.Search in Google Scholar PubMed
Wahner, A.D., Bronstein, J.M., Bordelon, Y.M., and Ritz, B. (2008). Statin use and the risk of Parkinson disease. Neurology 70: 1418–1422, https://doi.org/10.1212/01.wnl.0000286942.14552.51.Search in Google Scholar PubMed PubMed Central
Wakade, C., Chong, R., Bradley, E., Thomas, B., and Morgan, J. (2014). Upregulation of GPR109A in Parkinson’s disease. PLoS One 9: e109818, https://doi.org/10.1371/journal.pone.0109818.Search in Google Scholar PubMed PubMed Central
Wakade, C., Giri, B., Malik, A., Khodadadi, H., Morgan, J.C., Chong, R.K., and Baban, B. (2018). Niacin modulates macrophage polarization in Parkinson’s disease. J. Neuroimmunol. 320: 76–79, https://doi.org/10.1016/j.jneuroim.2018.05.002.Search in Google Scholar PubMed
Wang, X., Luo, S., Gan, X., He, C., and Huang, R. (2019). Safety and efficacy of ETC-1002 in hypercholesterolaemic patients: a meta-analysis of randomised controlled trials. Kardiol. Pol. 77: 207–216, https://doi.org/10.5603/kp.a2019.0013.Search in Google Scholar
Williams, D.M., Finan, C., Schmidt, A.F., Burgess, S., and Hingorani, A.D. (2020). Lipid lowering and Alzheimer disease risk: a mendelian randomization study. Ann. Neurol. 87: 30–39, https://doi.org/10.1002/ana.25642.Search in Google Scholar PubMed PubMed Central
Williams, E., John, N., Blackstone, J., Brownlee, W., Frost, C., Greenwood, J., and Chataway, J. (2019). TP1-11 MS-STAT2: a phase 3 trial of high dose simvastatin in secondary progressive multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 90: e13, https://doi.org/10.1136/jnnp-2019-abn.40.Search in Google Scholar
Williamson, J.D., Launer, L.J., Bryan, R.N., Coker, L.H., Lazar, R.M., Gerstein, H.C., Murray, A.M., Sullivan, M.D., Horowitz, K.R., and Ding, J. (2014). Cognitive function and brain structure in persons with type 2 diabetes mellitus after intensive lowering of blood pressure and lipid levels: a randomized clinical trial. JAMA Intern. Med. 174: 324–333, https://doi.org/10.1001/jamainternmed.2013.13656.Search in Google Scholar PubMed PubMed Central
Wolozin, B., Wang, S.W., Li, N.-C., Lee, A., Lee, T.A., and Kazis, L.E. (2007). Simvastatin is associated with a reduced incidence of dementia and Parkinson’s disease. BMC Med. 5: 1–11, https://doi.org/10.1186/1741-7015-5-20.Search in Google Scholar PubMed PubMed Central
Wu, J., Song, Y., Li, H., and Chen, J. (2009). Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. Eur. J. Clin. Pharmacol. 65: 1169–1174, https://doi.org/10.1007/s00228-009-0723-7.Search in Google Scholar PubMed
Yusuf, S., Islam, S., Chow, C.K., Rangarajan, S., Dagenais, G., Diaz, R., Gupta, R., Kelishadi, R., Iqbal, R., and Avezum, A. (2011). Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 378: 1231–1243, https://doi.org/10.1016/s0140-6736(11)61215-4.Search in Google Scholar
Zhan, S., Tang, M., Liu, F., Xia, P., Shu, M., and Wu, X. (2018). Ezetimibe for the prevention of cardiovascular disease and all‐cause mortality events. Cochrane Database Syst. Rev. 2018: CD012502, https://doi.org/10.1002/14651858.CD012502.pub2.Search in Google Scholar PubMed PubMed Central
Zhang, X.-L., Zhu, Q.-Q., Zhu, L., Chen, J.-Z., Chen, Q.-H., Li, G.-N., Xie, J., Kang, L.-N., and Xu, B. (2015). Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med. 13: 1–19, https://doi.org/10.1186/s12916-015-0358-8.Search in Google Scholar PubMed PubMed Central
Zhao, Y.Y., Weir, M.A., Manno, M., Cordy, P., Gomes, T., Hackam, D.G., Juurlink, D.N., Mamdani, M., Moist, L., and Parikh, C.R. (2012). New fibrate use and acute renal outcomes in elderly adults: a population-based study. Ann. Intern. Med. 156: 560–569, https://doi.org/10.7326/0003-4819-156-8-201204170-00401.Search in Google Scholar PubMed PubMed Central
Zhou, Y.-H., Ye, X.-F., Yu, F.-F., Zhang, X., Qin, Y.-Y., Lu, J., and He, J. (2013). Lipid management in the prevention of stroke: a meta-analysis of fibrates for stroke prevention. BMC Neurol. 13: 1–8, https://doi.org/10.1186/1471-2377-13-1.Search in Google Scholar PubMed PubMed Central
Ziff, O.J., Banerjee, G., Ambler, G., and Werring, D.J. (2019). Statins and the risk of intracerebral haemorrhage in patients with stroke: systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry 90: 75–83, https://doi.org/10.1136/jnnp-2018-318483.Search in Google Scholar PubMed
Zinan, Z., Xin, H., Zhang, Y., and Deping, L. (2020). Cardiovascular and safety events of PCSK9 inhibitors in statin-treated patients with cardiovascular risk: a systematic review and meta-analysis. J. Pharm. Pharmaceut. Sci. 23: 422–436, https://doi.org/10.18433/jpps31197.Search in Google Scholar PubMed
Zingel, R., Bohlken, J., Riedel-Heller, S., Barth, S., and Kostev, K. (2020). Association between low-density lipoprotein cholesterol levels, statin use, and dementia in patients followed in German general practices. J. Alzheim. Dis. 79: 1–10.10.3233/JAD-201176Search in Google Scholar PubMed
© 2023 Walter de Gruyter GmbH, Berlin/Boston
